NCT05557903 2022-09-28
Phase â… Clinical Study of Anti-CD52 Monoclonal Antibody in NHL and T-PLL
Lanzhou Institute of Biological Products Co., Ltd
Phase 1 Unknown
Clinical Trials
11 trialsNCT00363090 2013-09-20
Alemtuzumab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV T-Cell Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Phase 1/2 Unknown
NCT00562068 2013-08-26
Alemtuzumab and Combination Chemotherapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IV Peripheral T-Cell Lymphoma
National Cancer Institute (NCI)
Phase 1 Unknown
NCT00720447 2013-08-02
Donor Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00907036 2013-08-02
Fludarabine Phosphate, Melphalan, and Alemtuzumab Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed Hodgkin Lymphoma
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00908180 2013-08-02
Carmustine, Etoposide, Cytarabine, Melphalan, and Alemtuzumab Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00725231 2012-05-07
A-CHOP-14
University of Göttingen
Phase 3 Unknown
NCT00337519 2009-01-29
Allogeneic Stem Cell Transplantation in Chronic Lymphocytic Leukemia
Charite University, Berlin, Germany
Phase 2 Unknown
NCT00800943 2008-12-03
CRC005
Chronic Lymphocytic Leukemia Research Consortium
Phase 2 Unknown
NCT00157274 2007-04-03
Study of Alemtuzumab to Treat Advanced Mycosis Fungoides/Sezary Syndrome
Latin American Cooperative Onco-Haematology Group - Peru
Phase 2 Unknown
NCT00336206 2006-07-25
Low Dose Alemtuzumab for Consolidation and Maintenance of Patients With B-Cell Chronic Lymphocytic Leukemia
Tawam Hospital
Phase NA Unknown